Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia.
Treatment of severe aplastic anemia with antithymocyte globulin (ATG) and cyclosporin leads to clinical remission in a large proportion of patients. As many as 10% to 57% of these patients, however, develop paroxysmal nocturnal hemoglobinuria (PNH). We and others have observed that this secondary PNH appears to be more indolent than classical PNH, which results from an acquired mutation in the PIG-A gene. In the present study, we compared PIG-A mRNA transcripts in affected cells from patients with secondary PNH and patients with classical PNH. All four of our aplastic patients who developed PNH had a negative Ham test at diagnosis. Two of the four showed a positive Ham test within 3 months after ATG/cyclosporin administration, one developed a positive test at 6 months, and another at 18 months after immunosuppressive therapy. All four patients remain transfusion-independent with no thrombotic episodes after a mean follow-up of 30 months (range, 6 to 63 months). Reverse transcription-polymerase chain reaction (RT-PCR) of PIG-A transcripts in DAF-/CD59- neutrophils or lymphocyte lines of the four patients showed PIG-A abnormalities in all cases. Transition of C163 to T was found in one, a 14-bp deletion (positions 1141 to 1154) was found in the second, deletion of C39 was found in the third, and two mutations, transition of C55 to T and transversion of T762 to A, were found in the fourth. These abnormalities compared with findings of abnormal RNA splicing causing a 133-bp deletion, a 4-bp insertion (between positions 578 and 579), loss of A767, and loss of C575 in four patients with primary PNH. We conclude that secondary PNH that evolves out of aplastic anemia, like classical PNH, is associated with mutations in the PIG-A gene. The apparent indolent nature of this disease probably reflects early detection.
Nagarajan
S
S
Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Brodsky
R A
RA
Young
N S
NS
Medof
M E
ME
D000741:Anemia, Aplastic / Q000150:complications* / Q000235:genetics / Q000628:therapy; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001483:Base Sequence; D016572:Cyclosporine / Q000627:therapeutic use; D004252:DNA Mutational Analysis; D006457:Hemoglobinuria, Paroxysmal / Q000209:etiology / Q000235:genetics*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008565:Membrane Proteins / Q000172:deficiency / Q000235:genetics*; D008969:Molecular Sequence Data; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D012326:RNA Splicing; D012333:RNA, Messenger / Q000235:genetics; D017384:Sequence Deletion; D013601:T-Lymphocytes
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D008565:Membrane Proteins; D012333:RNA, Messenger; C080086:phosphatidylinositol glycan-class A protein; D016572:Cyclosporine